<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04793152</url>
  </required_header>
  <id_info>
    <org_study_id>13327</org_study_id>
    <nct_id>NCT04793152</nct_id>
  </id_info>
  <brief_title>Vancomycin Infusion Versus Intermittent Dosing (VIVID)</brief_title>
  <acronym>VIVID</acronym>
  <official_title>Does Dosing Vancomycin Continuously During Treatment of Serious Methicillin-resistant Staphylococcus Aureus Infections Reduce Nephrotoxicity Compared to Intermittent Dosing: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hamilton Health Sciences Corporation</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Intravenous vancomycin is considered first line therapy for serious methicillin-resistant&#xD;
      Staphylococcus aureus (MRSA) infections. The most common adverse effect of vancomycin is&#xD;
      nephrotoxicity. The risk of nephrotoxicity may depend on vancomycin dosing and chosen target.&#xD;
      Prior guidelines have recommended intermittent dosing and target trough level of 15-20mg/L.&#xD;
      Newer guidelines suggested targeting area under the curve over 24 hours (AUC) greater than&#xD;
      400. A feasible way of AUC guided dosing is continuous infusion targeting steady state&#xD;
      concentration of 17mg/L or greater. In prior observational studies, continuous infusion of&#xD;
      vancomycin was associated with a lower risk of nephrotoxicity. We will be conducting a&#xD;
      randomized controlled trial to compare continuous infusion and intermittent dosing of&#xD;
      intravenous vancomycin for serious MRSA infections in terms of nephrotoxicity.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Vancomycin induced nephrotoxicity</measure>
    <time_frame>28 days</time_frame>
    <description>Serum creatinine will be measured at enrolment as well as on day 1, 3, 5, 7, 14, 21 and 28. Nephrotoxicity is defined as an increase in serum creatinine by â‰¥44.2mmol/L or 50% since starting vancomycin compared to baseline. This increase in creatinine needs to occur while the patients is on vancomycin or within 7 days of discontinuation of vancomycin in order to be classified as vancomycin induced nephrotoxicity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for renal replacement therapy</measure>
    <time_frame>28 days</time_frame>
    <description>Need for renal replacement therapy for any reason while on vancomycin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical failure</measure>
    <time_frame>28 days</time_frame>
    <description>Clinical failure based on infectious diseases physician's clinical judgment requiring switch from intravenous vancomycin to another anti-MRSA antibiotic therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiologic failure</measure>
    <time_frame>28 days</time_frame>
    <description>Microbiologic failure based on demonstration of MRSA on repeated culture from the original sterile site (blood, lung, cerebral spinal fluid, bone, joint, peri-prosthetic joint, deep musculoskeletal tissue)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">480</enrollment>
  <condition>MRSA</condition>
  <arm_group>
    <arm_group_label>Vancomycin continuous infusion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A loading dose of 15-20mg/kg will be given followed by continuous infusion dose of 30mg/kg over 24 hours if normal renal function. Dose will be adjusted based on creatinine clearance. A random vancomycin level will be done with routine morning blood work until target level have been achieved. The dose is adjusted to target of 17-21mg/L based on target area under the curve of 400-500.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vancomycin intermittent dosing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A loading dose of 25mg/kg (maximum 2g) will be given to severely ill patients at the discretion of physician and pharmacist. The intermittent dose will be 15mg/kg every 12 hours if normal renal function. The frequency of dosing will be adjusted based on creatinine clearance. Trough level will be done before the fourth dose and adjusted to target trough level of 15-20mg/L.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vancomycin</intervention_name>
    <description>Administration as outlined</description>
    <arm_group_label>Vancomycin continuous infusion</arm_group_label>
    <arm_group_label>Vancomycin intermittent dosing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adult patients with serious MRSA infections based on culture results including&#xD;
             bacteremia, pneumonia, pleural space infection, central nervous system infection, bone&#xD;
             infection, septic arthritis, prosthetic joint infection, and deep abscess&#xD;
&#xD;
          -  Enrollment within 4 days from date of MRSA culture collection&#xD;
&#xD;
          -  Patient either currently not on vancomycin or has received vancomycin for 4 days or&#xD;
             less&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Acute kidney injury at time of recruitment&#xD;
&#xD;
          -  MRSA vancomycin minimum inhibitory concentration 2ug/mL or more&#xD;
&#xD;
          -  Patient is palliative or expected to die in the next 48 hours&#xD;
&#xD;
          -  History of type 1 hypersensitivity reaction to vancomycin&#xD;
&#xD;
          -  Creatinine clearance &lt;20 or on dialysis&#xD;
&#xD;
          -  Hypotensive shock requiring vasopressors or continuous renal replacement therapy at&#xD;
             time of recruitment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anthony D Bai, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anthony D Bai, MD</last_name>
    <phone>613-793-8577</phone>
    <email>anthony.bai@medportal.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mark Loeb, MD</last_name>
    <phone>905-525-9140</phone>
    <phone_ext>26679</phone_ext>
    <email>loebm@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Mark Loeb, MD</last_name>
      <phone>905-525-9140</phone>
      <phone_ext>26679</phone_ext>
      <email>loebm@mcmaster.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Joseph's Healthcare Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 4A6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <contact>
      <last_name>Zain Chagla, MD</last_name>
      <phone>905-525-9140</phone>
      <phone_ext>33998</phone_ext>
      <email>chaglaz@mcmaster.ca</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>March 8, 2021</study_first_submitted>
  <study_first_submitted_qc>March 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 11, 2021</study_first_posted>
  <last_update_submitted>March 10, 2021</last_update_submitted>
  <last_update_submitted_qc>March 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>vancomycin</keyword>
  <keyword>MRSA</keyword>
  <keyword>acute kidney injury</keyword>
  <keyword>intravenous infusions</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vancomycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

